Výsledky vyhledávání - "Ulrik Niels Lassen"

Supplementary Data from Tisotumab Vedotin in Previously Treated Recurrent or Metastatic Cervical Cancer

Supplementary Data

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::97c3d242be9bd2cff62fc2f7c9c1e709
https://doi.org/10.1158/1078-0432.22478142

Zobrazit plný text záznamu

Data from Tisotumab Vedotin in Previously Treated Recurrent or Metastatic Cervical Cancer

Purpose:Tissue factor (TF) is a potential target in cervical cancer, as it is frequently highly expressed and associated with poor prognosis. Tisotumab vedotin, a first-in-class investigational antibody–drug conjugate targeting TF, has demonstrated

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1f38b252c0896291d3186928e260eb23
https://doi.org/10.1158/1078-0432.c.6529863.v1

Zobrazit plný text záznamu

Overall survival (OS) of patients with TRK fusion–positive cancer receiving larotrectinib versus standard of care (SoC): A matching-adjusted indirect comparison (MAIC) using real-world data (RWD)

Autor: Carsten Bokemeyer, Noman Paracha, Ulrik Niels Lassen, Antoine Italiano, Sean D Sullivan, Marisca Marian, Marc Mardoche Fellous, Jesús García-Foncillas

Publikováno v: Journal of Clinical Oncology. 40:6579-6579

6579 Background: Larotrectinib trials in Tropomyosin Receptor Kinase (TRK) fusion cancer population were single arm trials and therefore limited comparative effectiveness data with larotrectinib are available.MAIC is typically used to balance populat

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::4a7fbae09df7f9a2605d468e17bb59ce
https://doi.org/10.1200/jco.2022.40.16_suppl.6579

Zobrazit plný text záznamu

Long-term control and safety of larotrectinib in a cohort of adult and pediatric patients with tropomyosin receptor kinase (TRK) fusion primary central nervous system (CNS) tumors

Autor: Sébastien Perreault, Alexander E. Drilon, Ulrik Niels Lassen, Birgit Geoerger, Karsten Nysom, Ingrid Øra, Igor T. Gavrilovic, Ricarda Norenberg, Marc Mardoche Fellous, Esther A. De La Cuesta, Theodore Willis Laetsch, Francois Doz, Cornelis Martinus van Tilburg

Publikováno v: Journal of Clinical Oncology. 40:2010-2010

2010 Background: Neurotrophic tyrosine receptor kinase ( NTRK) gene fusions are known oncogenic drivers in a variety of tumor types. Larotrectinib is a highly selective, CNS-active TRK inhibitor that demonstrated an objective response rate (ORR) of 3

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::a8174bb6e2224e70cebf3a881cca115f
https://doi.org/10.1200/jco.2022.40.16_suppl.2010

Zobrazit plný text záznamu

Indirect assessment of tumor-infiltrating lymphocyte activity in serum for predicting outcome in patients with glioblastoma treated with immunotherapy in the recurrent setting

Autor: Christina Jensen, Simone Bendix Maarup, Hans Skovgaard Poulsen, Benedikte Hasselbalch, Morten A. Karsdal, Inge Marie Svane, Ulrik Niels Lassen, Nicholas Willumsen

Publikováno v: Journal of Clinical Oncology. 40:2059-2059

2059 Background: Glioblastoma (GBM) is an aggressive brain tumor and despite efforts in developing new effective therapies, patient survival remains low. There is increasing interest in using immune checkpoint inhibitors (ICIs) for GBM, however the i

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::ad7909bb0295a7d214da6221cf0ff587
https://doi.org/10.1200/jco.2022.40.16_suppl.2059

Zobrazit plný text záznamu

Larotrectinib efficacy and safety in adult TRK fusion cancer patients

Autor: David S. Hong, Shivaani Kummar, Anna F. Farago, Ulrik Niels Lassen, Jordan Berlin, Russell J. Schilder, Raymond S. McDermott, Jyoti D. Patel, Afshin Dowlati, Robert Charles Doebele, Daniel Shao-Weng Tan, James J. Lee, Shivani Nanda, Barrett H. Childs, Nora Ku, Alexander E. Drilon, David Michael Hyman

Publikováno v: Journal of Clinical Oncology. 37:3122-3122

3122 Background: A broad range of pediatric and adult malignancies harbor TRK fusions involving the NTRK1, NTRK2, and NTRK3 genes. The highly-selective TRK inhibitor, larotrectinib, has previously shown a high overall response rate (ORR) and a favora

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::d2c4facdac6df5da529a6430b8abf039
https://doi.org/10.1200/jco.2019.37.15_suppl.3122

Zobrazit plný text záznamu

A phase 2 study on efficacy, safety and intratumoral pharmacokinetics of oral selinexor (KPT-330) in patients with recurrent glioblastoma (GBM)

Autor: Ulrik Niels Lassen, Morten Mau-Soerensen, Andrew L. Kung, Patrick Y. Wen, Eudocia Quant Lee, Scott R. Plotkin, Aida Muhic, Tami Rashal, Tony Williams, Dilara McCauley, Joel Ellis, Jean-Richard Saint-Martin, Robert Carlson, Ran Frenkel, Sharon Shacham, Mansoor Raza Mirza, Michael Kauffman, Andrew B. Lassman

Publikováno v: Journal of Clinical Oncology. 33:2044-2044

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::bc34791f497244775fb1a1ba839c5893
https://doi.org/10.1200/jco.2015.33.15_suppl.2044

Zobrazit plný text záznamu

A first-in-class, first-in-human phase I trial of KPT-330 (selinexor), a selective inhibitor of nuclear export (SINE) in patients (pts) with advanced solid tumors

Autor: Morten Mau-Soerensen, Albiruni R. A. Razak, Anthony Frank Shields, Nashat Y. Gabrail, John F. Gerecitano, Sharon Shacham, Ulrik Niels Lassen, Tami Rashal, Jennifer Cooksey, Yosef Landesman, Gregory Pond, Amit M. Oza, Michael Kauffman, Lillian L. Siu, Philippe L. Bedard, Hemchandra Mahaseth, Mansoor Raza Mirza, Amit Mahipal

Publikováno v: Journal of Clinical Oncology. 32:2537-2537

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::de97cbad672bec6db931775e920aea4d
https://doi.org/10.1200/jco.2014.32.15_suppl.2537

Zobrazit plný text záznamu

Updated efficacy and safety of larotrectinib in patients with tropomyosin receptor kinase (TRK) fusion lung cancer

Autor: Alexander E. Drilon, Jessica Jiyeong Lin, Shivaani Kummar, Daniel Shao-Weng Tan, Jyoti D. Patel, Ulrik Niels Lassen, Serge Leyvraz, Victor Moreno, Lee S. Rosen, Benjamin Maurice Solomon, Jeffrey Yachnin, Yongmei Liu, Ming-Shen Dai, Ricarda Norenberg, Marc Mardoche Fellous, Chiara Erminia Mussi, Lin Shen

Publikováno v: Web of Science

9024 Background: Neurotrophic tyrosine receptor kinase ( NTRK) gene fusions have been identified as oncogenic drivers in a variety of tumor types, including lung cancer. Larotrectinib is a highly selective, central nervous system (CNS)-active TRK inh

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1aae328041f604c26e9a9ab020d2bc3b
https://publons.com/wos-op/publon/55424293/

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání